Dogwood Therapeutics, Inc.
Key Metrics
- Previous Close
- $1.08
- 52-Week Range
- $0.90 – $7.04
- Market Cap
- $41.29M
- P/E (TTM)
- 0.11
- EPS (TTM)
- 10.26
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.57
- PEG Ratio
- —
- Return on Equity
- -35.58%
- Return on Assets
- -13.88%
- Gross Margin
- 11.90%
- Operating Margin
- -18608.44%
- Profit Margin
- 0.00%
- Current Ratio
- 2.78
- Debt/Equity
- 0.00
- Total Debt
- $117.95K
- Free Cash Flow
- $-9.85M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $36.46M
Market Snapshot
About
Dogwood Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases with significant unmet medical needs. The company's pipeline includes novel therapeutic candidates targeting various conditions, with a focus on precision medicine approaches. As a development-stage company, Dogwood is advancing its drug candidates through clinical trials and regulatory processes. The company does not yet have any commercialized products and generates no product revenue.